Should I Buy ACIU? ACIU 2026 Analysis

Should You Buy AC Immune SA (ACIU) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.140

1 Day change

6.08%

52 Week Range

4.000

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: no proprietary buy signals, weak-to-neutral technicals below the pivot, and fundamentals are deteriorating (2025/Q3).
Near-term edge looks unfavorable: pattern-based stats imply modest downside over the next day/week, with only a small positive bias over the next month.
Options positioning is extremely call-heavy, but the tape is illiquid and IV is extreme, which reads more like speculative “lotto” interest than reliable bullish conviction.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock today.

Technical Analysis

Price context: last close ~$3.29, below Pivot 3.504 → trend bias is neutral-to-bearish until reclaiming that level.
MACD: histogram -0.0464 (below 0) but negatively contracting → selling pressure may be easing, yet momentum remains bearish.
RSI(6): 44.4 → neutral, not showing a strong oversold bounce signal.
Moving averages: converging → compression/range behavior; break direction matters.
Key levels: Support S1 3.225 (near current price), then S2 3.053. Resistance at Pivot 3.504, then R1 3.783.
Short-horizon odds (pattern analogs): ~50% chance of -1.08% next day, -2.38% next week, +2.85% next month.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment skew: Put/Call OI = 0.04 (calls dominate) and put volume = 0 today → superficially bullish skew.
Volatility regime is extreme: IV 30D ~358.8% vs HV ~90.9%, IV percentile ~90.8 → pricing implies very large moves; this often accompanies speculative trading.
Liquidity caveat: today’s option volume = 8 contracts (very low) → option ratios may be noisy/unreliable as a sentiment read.
Open interest: calls 11,124 vs puts 392 → positioning heavily tilted to calls, but without strong confirmation from volume.

Technical Summary

Sell

Buy

Positive Catalysts

- Technical: price is sitting close to S1 (3.225), which can produce a short-term bounce if it holds.
- Options: very call-heavy open interest could support upside attempts if the stock reclaims 3.50+ (pivot).
- MACD contraction suggests downside momentum may be slowing.

Neutral/Negative Catalysts

- Technical: still below pivot (3.504) with MACD negative → rallies may be sold until that level is reclaimed.
- Statistical near-term bias points to slight downside over the next day/week.
- Options market is extremely high-IV and illiquid today → higher risk of whipsaws and unreliable sentiment signals.
- No recent news/catalysts provided to justify a fast re-rating upward.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: $0.939M, -96.32% YoY → sharp contraction.
Net income: -$15.86M, down -388.17% YoY → losses widened significantly.
EPS: -0.16, down -420% YoY → earnings trend worsening.
Gross margin: 100% (likely reflects very small revenue base / mix effects), not enough to offset the scale of losses.
Overall: financial trend is negative, offering little support for an “impatient” buy-the-now setup.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating trend or price target change data was provided here, so Wall Street consensus cannot be confirmed from this dataset.
Practical pro/con without the analyst feed: Pros would be any pipeline/biotech optionality implied by high IV and call OI; Cons are the severe revenue collapse and widening losses, which typically keep institutional conviction muted.
Influential/political activity: No recent Congress trading data available; hedge funds and insiders are reported as neutral with no significant recent trends.

1 Analyst Rating

Wall Street analysts forecast ACIU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACIU is 12 USD with a low forecast of 12 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.960

Low

Averages

High

Current: 2.960

Low

Averages

High

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$16

AI Analysis

2025-04-03

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$16

AI Analysis

2025-04-03

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$16

2025-03-14

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$16

2025-03-14

Reiterates

Strong Buy

Reason

ACIU Should I Buy

ACIU Should I Buy

Should You Buy AC Immune SA (ACIU) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch